Class 1 innovative drug clinical trials share
RecordSTO-8SY5MKW0ZB-KK7QPKFSF9-VTW4MP
China · 2025
Class 1 innovative drug clinical trials share in China was 72.4% in 2025 (NHSA).
Clinical trial registrations in China: every year, the rank and how it is measured
- Publisher
- NHSA
- Authority tier
- T1 Official
- Locator
- 新药临床试验近六成 其中超七成是创新药
- Retrieved
- 17 Sep 2026
- Status
- Verified
What the source says
报告显示，2025年我国登记的2997项新药临床试验中，1类创新药有2171项，占比72.4%，同比增长4.1%；1类创新药临床试验抗肿瘤药物占比较高，占总体的37.5%。
Checked: the figure 72.4%is stated in this passage. If it does not match, the extraction is wrong and we want to know.
Cite this figure
APA
National Healthcare Security Administration. (2025). 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_8SY5MKW0ZBKK7QPKFSF9VTW4MP
Other formats: MLA, Chicago, BibTeX
- MLA
- National Healthcare Security Administration. "从“0”到“1”创新能力增强 我国新药研发热度持续攀升." 2025, http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Accessed 17 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_8SY5MKW0ZBKK7QPKFSF9VTW4MP.
- Chicago
- National Healthcare Security Administration. "从“0”到“1”创新能力增强 我国新药研发热度持续攀升." 2025. http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Accessed September 17, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_8SY5MKW0ZBKK7QPKFSF9VTW4MP.
- BibTeX
- @misc{nhsa2025classvtw4mp, author = {{National Healthcare Security Administration}}, title = {从“0”到“1”创新能力增强 我国新药研发热度持续攀升}, year = {2025}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_8SY5MKW0ZBKK7QPKFSF9VTW4MP}, note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\_14\_21076.html. Accessed September 17, 2026.} }
Data published under CC BY 4.0. The citation credits the original publisher and links to this permanent record.
Provenance and verification
Everything needed to check this number yourself, without taking our word for it.
Primary source
- Publisher
- National Healthcare Security Administration · homepage ↗
- Authority tier
- Tier 1 · Multilateral Official
- Report
- 从“0”到“1”创新能力增强 我国新药研发热度持续攀升
- Type
- Press release
- Published
- —
- Locator
- 新药临床试验近六成 其中超七成是创新药
- Retrieved
- 17 September 2026
- Link status
- Reachable (HTTP 200)
- Report licence
- See source
Verification
- Status
- Verified
- Review protocol
- Editorial review
- Checked on
- 17 September 2026
- Last revision
- 17 September 2026
- Permanent URL
- /stat/stat_8SY5MKW0ZBKK7QPKFSF9VTW4MP